Iovance Biotherapeutics, Inc. (IOVA) saw its stock plummet 6.32% in pre-market trading, following a significant price target cut by Chardan Capital Markets. The sharp decline comes as investors react to the lowered expectations for the biotechnology company's stock performance.

Chardan reduced its price target for Iovance Biotherapeutics from $20 to $17, representing a 15% decrease. Despite the cut, Chardan maintained its "Buy" rating on the stock. This move contrasts with the broader analyst consensus, which, according to FactSet, rates IOVA as "overweight" with a mean price target of $7.75. The disparity between Chardan's new target and the average suggests a wide range of opinions among analysts regarding the company's prospects.

The market's strong negative reaction to the price target cut highlights investor sensitivity to changing analyst perspectives, especially in the volatile biotechnology sector. While Chardan's maintained "Buy" rating indicates some optimism, the significant pre-market drop suggests that investors are more focused on the near-term implications of the lowered price target. As the regular trading session begins, market participants will be closely watching IOVA's performance to gauge whether this pre-market plunge is a temporary setback or the start of a more prolonged downturn.